Back to Results
First PageMeta Content
Rare diseases / Fabry disease / Lysosomal storage diseases / Renal function / Biomarker / Enzyme replacement therapy / Clinical trial / ERT / Glycogen storage disease type II / Medicine / Health / Clinical research


Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Add to Reading List

Document Date: 2014-12-02 16:03:24

Open Document

File Size: 109,34 KB

Share Result on Facebook

City

Dallas / /

Company

Amicus Therapeutics Inc. / Fabry Support & Information Group / /

Country

United States / Canada / /

Event

Conference Call / /

Facility

Baylor Research Institute / Institute of Metabolic Disease / /

IndustryTerm

biopharmaceutical / Web participants / therapies for rare and orphan diseases / treatment for Fabry disease / candidate drug products / corporate web site / /

MedicalCondition

disease / Fabry disease / lysosomal storage diseases / human genetic diseases / Pompe disease / orphan diseases / /

MedicalTreatment

enzyme replacement therapies / Enzyme Replacement Therapy / /

Organization

Institute of Metabolic Disease / Baylor Research Institute / /

Person

Raphael Schiffmann / John F. Crowley / Jack Johnson / /

/

Position

investigator / Executive Director / Chairman and Chief Executive Officer / Private / /

Product

Fabrazyme / /

Technology

alpha / /

URL

http /

SocialTag